μλ₯΄ννλ΄
μλ₯΄ννλ΄μ μ΄λ―Ένλ΄ λ° λ©λ‘νλ΄κ³Ό ꡬ쑰μ μΌλ‘ μ μ¬νμ§λ§ νκ· μ€ννΈλΌμ΄ λ μ’μ κ΄λ²μ **μΉ΄λ°νλ΄κ³ νμμ **μ λλ€. * **μ£Όμ μ°¨μ΄μ :** λ€λ₯Έ μΉ΄λ°νλ΄κ³μ λ¬λ¦¬ **λ Ήλκ· (Pseudomonas aeruginosa)**μ΄λ **μμλ€ν λ°ν°(Acinetobacter)**μλ ν¨κ³Όκ° μμ΅λλ€. * **μμμ μ μ©μ±:** μλ―Έλ ΈκΈλ¦¬μ½μ¬μ΄λκ³ μ½λ¬Όμ΄ κΈκΈ°μ΄κ±°λ(μ: μ λΆμ ) ν¨κ³Όκ° μκ³ λ©λ‘νλ΄μ μ¬μ©ν μ μμ λ λ΄μ± κ·Έλ μμ±κ· κ°μΌμ μΉλ£νλ λ° νΉν μ μ©ν©λλ€. * **μμνμ μ¬μ©:** νμ¬ κ°μ κ³ μμ΄μμμ μ¬μ©μ λν μ 보λ λ§€μ° μ νμ μ΄λ©°, μμνμμλ **μνμ μ¬μ©**μΌλ‘ κ°μ£Όλ©λλ€.
μμ© κΈ°μ : Ertapenem is a **beta-lactam antibiotic** that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. * **Mechanism:** It binds to **penicillin-binding proteins (PBPs)** β inhibits peptidoglycan cross-linking β weakens the bacterial cell wall β causes cell lysis and death. * **Enzyme Stability:** It is highly resistant to degradation by most beta-lactamases, including penicillinases and cephalosporinases. * **Renal Stability:** Unlike imipenem, ertapenem is stable against renal **dehydropeptidase I**, meaning it does *not* require co-administration with cilastatin.
λλ¬Ό μ’ λ³ μ©λ
- Susceptible infections (Investigational) Β· 15 mg/kg IV or IM every 12 hours (not to exceed a daily dosage of 1 gram) Β· IV/IM Β· q12h Β· Monitor literature for additional data.
- Susceptible infections (Investigational) Β· 15 mg/kg IV or IM every 12 hours (not to exceed a daily dosage of 1 gram) Β· IV/IM Β· q12h Β· Monitor literature for additional data.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to ertapenem or other carbapenems
- History of anaphylaxis to any beta-lactam antibiotic
- Hypersensitivity to lidocaine or amide-type local anesthetics (if using 1% lidocaine as an IM diluent)
μ΄μλ°μ
- Injection site reactions (most common in humans)
- Gastrointestinal effects (nausea, vomiting, diarrhea)
- Headache
- Tachycardia
- Hypersensitivity reactions (rare)
- CNS effects (hallucinations, agitation, seizures - rare)
μ½λ¬Ό μνΈμμ©
- Probenecid Β· Can increase ertapenem AUC by 25% and elimination half-life by about 20%. Not recommended to be used concurrently to extend half-life.
λͺ¨λν°λ§
- Clinical efficacy (WBC count, resolution of fever, etc.)
- Adverse effects (GI signs, neurotoxicity, hypersensitivity)
- Hepatic, hematopoietic, and renal function (suggested for periodic assessment during prolonged use)
κ³Όμ©λ
Inadvertent overdoses are unlikely. In humans, a 3-gram IV dose caused an increased incidence of nausea and diarrhea. If overdose occurs and adverse effects are noted, treat supportively.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.